McNicholasWTBonsigoreMR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J. 2007;29(1):156–178.
2.
ChobanianAVBakrisGLBlackHR. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572.
3.
ParatiGLombardiCHednerJ. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens. 2012;30(4):633–646.
4.
NenaEPapanasNSteiropoulosP. Mean Platelet Volume and Platelet Distribution Width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity?Platelets. 2012;23(6):447–454.
5.
KostapanosMSMikhailidisDPElisafMSSteiropoulosPPapanasN. Obstructive sleep apnoea syndrome and cardiovascular risk. Arch Med Sci. 2012;8(6):1115–1116.
6.
YorgunHKabakçıGCanpolatU. Predictors of blood pressure reduction with nocturnal continuous positive airway pressure therapy in patients with obstructive sleep apnea and prehypertension. Angiology. 2014;65(2):98–103.
7.
SteiropoulosPPapanasNNenaE. Markers of glycemic control and insulin resistance in non-diabetic patients with obstructive sleep apnea hypopnea syndrome: does adherence to CPAP treatment improve glycemic control?Sleep Med. 2009;10(8):887–891.
8.
NenaESteiropoulosPTzouvelekisA. Reduction of serum retinol-binding protein-4 levels in nondiabetic obstructive sleep apnea patients under continuous positive airway pressure treatment. Respiration. 2010;80(6):517–523.
9.
RobinsonGVLangfordBASmithDMStradlingJR. Predictors of blood pressure fall with continuous positive airway pressure (CPAP) treatment of obstructive sleep apnoea (OSA). Thorax. 2008;63(10):855–859.
10.
BarbéFDuran-CantollaJCapoteF. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010;181(7):718–726.
11.
NenaESteiropoulosPPapanasN. Sleepiness as a marker of glucose deregulation in obstructive sleep apnea. Sleep Breath. 2012;16(1):181–186.
12.
KostapanosMSElisafMSMikhailidisDP. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Curr Med Res Opin. 2012;28(9):1415–1419.
13.
Sánchez-de-la-TorreMMedianoOBarcelóA. The influence of obesity and obstructive sleep apnea on metabolic hormones. Sleep Breath. 2012;16(3):649–656.
14.
RizzoMRizviAASudarE. A review of the cardiovascular and anti-atherogenic effects of ghrelin [published online December 26, 2012]. Curr Pharm Des. 2012.
15.
VarlamiVMalakasiotiGAlexopoulosEI. Low-grade albuminuria in children with obstructive sleep apnea [published online December 10, 2012]. J Sleep Res. 2012.
16.
LioudakiEFlorentinMGanotakisESMikhailidisDP. Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals [published online December 26, 2012]. Curr Pharm Des. 2012.
17.
DragerLFLopesHFMaki-NunesC. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One. 2010;5(8):e12065.
18.
KatsikiNKaragiannisAAthyrosVGMikhailidisDP. Hyperuricaemia: more than just a cause of gout [published online October 1, 2012]. J Cardiovasc Med (Hagerstown). 2012.
19.
TanKCChowWSLamJC. HDL dysfunction in obstructive sleep apnea. Atherosclerosis. 2006;184(2):377–382.
20.
Otocka-KmiecikAMikhailidisDPNichollsSJDavidsonMRyszJBanachM. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease. Prog Lipid Res. 2012;51(4):314–324.
21.
ToyamaYChinKChiharaY. Association between sleep apnea, sleep duration and serum lipid profile in an urban male working population in Japan [published online October 15, 2012]. Chest. 2012.
22.
WierzbickiASClarkeREViljoenAMikhailidisDP. Triglycerides: a case for treatment?Curr Opin Cardiol. 2012;27(4):398–404.
23.
MussoGOlivettiCCassaderMGambinoR. Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: emerging evidence and mechanisms. Semin Liver Dis. 2012;32(1):49–64.
24.
AthyrosVGTziomalosKDaskalopoulosGNKaragiannisAMikhailidisDP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?Ann Med. 2011;43(3):167–171.
